DiaBridge AB
556979-7995ActiveDeveloping breakthrough drugs targeting DNA repair for cancer and inflammation.
Biotechnology/Pharmaceutical Companyoxcia.com
Yleiskatsaus
- 0
- Työntekijät
- ≤1t SEK
- Liikevaihto
- 2014
- Perustettu
Avainpäättäjät
Ulrika Warpman Berglund
CEO
@oxcia.com+46732XXXXXX
Gustaf Eriksson
Member of the Board
@atek.nu
Ingvar Karlsson
Member of the Board
@oxcia.com
Thomas Helleday
Member of the Board
@oxcia.com
+5 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Oxcia AB is a science-led Swedish biotechnology company focused on revolutionizing treatments for cancer and inflammation. The core of their innovation lies in the unique O2-DDR technology platform, which manages oxidative stress, oxidative DNA damage, and the DNA Damage Response (DDR) in cells. Thi...